Markets:

Overview

News

Currencies

International

Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

11.35 -0.22 (-1.90%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

32 33 Next >

Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More ↗

March 20, 2023

Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered

Via Benzinga

The "Rags-To-Riches" Portfolio: An Update ↗

March 18, 2023

Cannabis, psychedelic, and plant-based food stocks performed extremely poorly in 2022, down 73% vs. 2021 but perhaps some of them will bounce back with major returns in 2023.

Via Talk Markets

Psychedelic Stock Gainers And Losers From March 17, 2023 ↗

March 17, 2023

Via Benzinga

Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today ↗

March 16, 2023

Via Benzinga

Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today ↗

March 15, 2023

Via Benzinga

Where Compass Pathways Stands With Analysts ↗

March 10, 2023

Via Benzinga

Earnings Preview: Compass Pathways ↗

February 27, 2023

Via Benzinga

COMPASS Pathways: New Data & Insight On Psilocybin Therapy For Treatment-Resistant Depression ↗

March 14, 2023

COMPASS Pathways' (NASDAQ: CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with psychological support for Treatment-Resistant Depression (TR

Via Benzinga

Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today ↗

March 14, 2023

Via Benzinga

ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today ↗

March 13, 2023

Via Benzinga

Seelos Therapeutics, GH Research Among Top Psychedelic Movers Of Today ↗

March 10, 2023

Via Benzinga

Psychedelic Stock Gainers And Losers From March 9, 2023 ↗

March 09, 2023

Via Benzinga

Numinus Wellness, Seelos Therapeutics Among Top Psychedelic Movers Of Today ↗

March 08, 2023

Via Benzinga

Cybin, GH Research Among Top Psychedelic Movers Of Today ↗

March 07, 2023

Via Benzinga

Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More ↗

March 07, 2023

Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been...

Via Benzinga

Compass Pathways - Entering A Brave New World ↗

March 07, 2023

A look at what Compass Pathways is focused on, its clinical trial progress to date, its latest quarterly financials, the history of its stock price performance, and the price forecasts for the stock...

Via Talk Markets

Psychedelic Stock Gainers And Losers From March 6, 2023 ↗

March 06, 2023

Via Benzinga

Here Are The Year's Highest Priced Psychedelics Stocks In US Markets ↗

March 06, 2023

After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.

Via Benzinga

2 Potentially Explosive Growth Stocks Down 30% or More to Buy for the Next Bull Market ↗

March 06, 2023

Investing now is an admittedly risky bet, but the payoff could be massive.

Via The Motley Fool

2 Growth Stocks With Incredible Potential in the Next 5 Years ↗

March 06, 2023

Neither is profitable, but both could be on the verge of massive booms in revenue.

Via The Motley Fool

Cybin, GH Research Among Top Psychedelic Movers Of Today ↗

March 03, 2023

Via Benzinga

Psychedelic Stock Gainers And Losers From March 2, 2023 ↗

March 02, 2023

Via Benzinga

Cybin, GH Research Among Top Psychedelic Movers Of Today ↗

March 01, 2023

Via Benzinga

Psychedelic Stock Gainers And Losers From February 28, 2023 ↗

February 28, 2023

Via Benzinga

COMPASS Pathways Shares Q4 & Year-End 2022 Financials, Advances Phase 3 Psilocybin Trials ↗

February 28, 2023

Mental healthcare biotech COMPASS Pathways (NASDAQ: CMPS) reported its financial results for the fourth quarter and year-end 2022 and provided an update on recent pipeline and business progress....

Via Benzinga

Compass Pathways Plc (CMPS) Q4 2022 Earnings Call Transcript ↗

February 28, 2023

CMPS earnings call for the period ending December 31, 2022.

Via The Motley Fool

COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights

February 28, 2023

From COMPASS Pathways

Via GlobeNewswire

Psychedelic Stock Gainers And Losers From February 27, 2023 ↗

February 27, 2023

Via Benzinga

Of The 6 Largest Psychedelic Drug Stocks, Only One Has Not Advanced YTD ↗

February 26, 2023

The most critical financial information on the health of a company is whether, or not, it has a Net Positive Operating Cash Flow; its Altman -Z Score; its Piotroski F-Score; and the percentage...

Via Talk Markets

Psychedelic Stock Gainers And Losers From February 24, 2023 ↗

February 24, 2023

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

32 33 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.